Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors

References

• Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci U S A 2000;97:13708–13.
   PubMed Web of Science ®Google Scholar
• De Ruijter AJM, Van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737–49.
   PubMed Web of Science ®Google Scholar
• Foglietti C, Filocamo G, Cundari E, et al. Dissecting the biological functions of drosophila histone deacetylases by RNA interference and transcriptional profiling. J Biol Chem 2006;281:17968–76.
   PubMed Web of Science ®Google Scholar
• Zhang L, Han YT, Jiang QX, et al. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy. Med Res Rev 2015;35:63–84.
   PubMed Web of Science ®Google Scholar
• Gronroos E, Hellman U, Heldin CH, Ericsson J. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 2002;10:483–93.
   PubMed Web of Science ®Google Scholar
• Giandomenico V, Simonsson M, Gronroos E, Ericsson J. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol Cell Biol 2003;23:2587–99.
   PubMed Web of Science ®Google Scholar
• Jin YH, Jeon EJ, Li QL, et al. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 2004;279:29409–17.
   PubMed Web of Science ®Google Scholar
• Bode AM, Dong ZG. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793–805.
   PubMed Web of Science ®Google Scholar
• Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004;5:392–401.
   PubMed Web of Science ®Google Scholar
• Kovacs JJ, Murphy PJM, Gaillard S, et al. HDAC6 regulates hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601–7.
   PubMed Web of Science ®Google Scholar
• Patel MM, Patel BM. Repurposing of sodium valproate in colon cancer associated with diabetes mellitus: role of HDAC inhibition. Eur J Pharm Sci 2018;121:188–99.
   PubMed Web of Science ®Google Scholar
• Soragni E, Xu C, Cooper A, et al. Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases. Methods Mol Biol 2011;793:495–508.
   PubMedGoogle Scholar
• Mai A, Rotili D, Valente S, Kazantsev AG. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des 2009;15:3940–57.
   PubMed Web of Science ®Google Scholar
• Cantley MD, Haynes DR. Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs. Inflammopharmacology 2013;21:301–7.
   PubMed Web of Science ®Google Scholar
• Saiyed ZM, Gandhi N, Agudelo M, et al. HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND). Neurochem Int 2011;58:656–64.
   PubMed Web of Science ®Google Scholar
• Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS 2011;6:25–9.
   PubMed Web of Science ®Google Scholar
• Ylisastigui L, Archin NM, Lehrman G, et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004;18:1101–8.
   PubMed Web of Science ®Google Scholar
• Gallo P, Latronico MV, Gallo P, et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res 2008;80:416–24.
   PubMed Web of Science ®Google Scholar
• Kook H, Lepore JJ, Gitler AD, et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein hop. J Clin Invest 2003;112:863–71.
   PubMed Web of Science ®Google Scholar
• Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194–202.
   PubMed Web of Science ®Google Scholar
• Bian J, Zhang LH, Han YT, et al. Histone deacetylase inhibitors: potent anti-leukemic agents. Curr Med Chem 2015;22:2065–74.
   PubMed Web of Science ®Google Scholar
• Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998;95:3003–7.
   PubMed Web of Science ®Google Scholar
• Ueda H, Nakajima H, Hori Y, et al. Fr901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994;47:301–10.
   PubMed Web of Science ®Google Scholar
• Yang L, Xue XW, Zhang YH. Simple and efficient synthesis of belinostat. Synth Commun 2010;40:2520–4.
   Web of Science ®Google Scholar
• Neri P, Bahlis NJ, Lonial S. Panobinostat for the treatment of multiple myeloma. Expert Opin Investig Drugs 2012;21:733–47.
   PubMed Web of Science ®Google Scholar
• Dong M, Ning Z, Newman MJ, et al. Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. J Clin Oncol 2009;27:3529.
   Web of Science ®Google Scholar
• Enders TA, Strader LC. Auxin activity: past, present, and future. Am J Bot 2015;102:180–96.
   PubMed Web of Science ®Google Scholar
• Kline BE, Rusch HP. Tumor inhibitor studies. II. The effect of plant hormones on tumor growth. Cancer Res 1943;3:702–5.
   Google Scholar
• Bian J, Luan Y, Wang C, Zhang L. Discovery of n-hydroxy-4-(1h-indol-3-yl)butanamide as a histone deacetylase inhibitor. Drug Discov Ther 2016;10:163–6.
   PubMed Web of Science ®Google Scholar
• McClure J, Zhang C, Inks E, et al. Development of allosteric hydrazide-containing class I histone deacetylase inhibitors for use in acute myeloid leukemia. J Med Chem 2016;59:9942–59.
   PubMed Web of Science ®Google Scholar